The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Latest Cancer News

FDA Approves Opdivo for Renal Cell Carcinoma (11-25-2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung... Continue Reading

Ninlaro® Approved for Multiple Myeloma (11-23-2015)

The United States Food and Drug Administration (FDA) has granted approval to Ninlaro® (ixazomib) for the treatment of multiple myeloma. This marks the third drug approved this year for the treatment of multiple myeloma. The approval specifies that Ninlaro... Continue Reading

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer (11-19-2015)

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell... Continue Reading

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia (11-18-2015)

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic... Continue Reading

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma (11-17-2015)

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Darzalex appears to be effective... Continue Reading

New Lab Test Enables Precision Treatment for Lung Cancer (11-16-2015)

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer... Continue Reading

Does Processed Meat Cause Colorectal Cancer? (11-16-2015)

According to the International Agency for Research on Cancer (IARC), eating processed meat products can increase a person’s risk for developing colorectal cancer. Processed meat is classified as meat that has been salted, cured, fermented, or smoked... Continue Reading

National "Check Yourself to Protect Yourself ALL YEAR" Campaign Highlights Need for Year-Round Skin Cancer Prevention (11-12-2015)

Although one in five Americans will get skin cancer in their lifetimes, 65 percent of people of color don’t believe they are at risk and face lower survival rates as a result. To change these odds, the cancer organization Patients Rising will use... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (11-10-2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (11-9-2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (11-5-2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer.... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (11-4-2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Next Page »